Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?

Core Points - VTv Therapeutics' stock is experiencing a significant decline due to the FDA placing a clinical hold on its cadisegliatin clinical program, which includes the TT1 Phase 3 trial for type 1 diabetes [1][4] - The clinical hold requires the company to conduct an in vitro study to characterize a chromatographic signal observed in a human absorption, distribution, metabolism, and excretion (ADME) study [2][3] - As a result of the news, VTv Therapeutics' stock is down 45.7% as of Monday morning, with trading volume exceeding 10,000 shares, slightly below the daily average of approximately 15,000 shares [3][4] Company Response - VTv Therapeutics' chairman, president, and CEO, Paul Sekhri, emphasized that patient safety is the company's top priority and expressed appreciation for the FDA's thoroughness in understanding the signal [2][3] - The company is actively working with the FDA to resolve the clinical hold and aims to resume enrollment in the trial as quickly as possible [3]